Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) Short Interest Down 85.7% in October

Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) was the recipient of a large decrease in short interest during the month of October. As of October 31st, there was short interest totalling 100 shares, a decrease of 85.7% from the October 15th total of 700 shares. Based on an average daily volume of 3,500 shares, the days-to-cover ratio is currently 0.0 days.

Santen Pharmaceutical Price Performance

OTCMKTS:SNPHY traded up $0.16 during trading hours on Wednesday, reaching $10.78. The company’s stock had a trading volume of 1,357 shares, compared to its average volume of 6,332. The firm has a 50-day simple moving average of $12.06 and a 200-day simple moving average of $11.29. Santen Pharmaceutical has a 1 year low of $8.72 and a 1 year high of $13.00.

About Santen Pharmaceutical

Santen Pharmaceutical Co, Ltd. engages in the research and development, manufacture, and marketing of pharmaceuticals and medical devices in Japan and internationally. Its product portfolio includes tafluprost/timolol maleate, a prostaglandin F2a derivative and a beta-adrenergic receptor blocker; and netarsudil mesilate and latanoprost, a prostaglandin F2a derivative which is marketing approval phase for the treatment of glaucoma and ocular hypertension.